No profile data available.
Innate Pharma S.a. (IPHA) is a healthcare company in the additional cancer treatment drugs industry, based in Marseille, France, with about 120 full-time employees.
It reported revenue of 2.79 million EUR for fiscal year 2025, down 77.9% from fiscal year 2024, and net income of -49.18 million EUR. Its market capitalization was $180.95 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Innate Pharma reported 2.79 million EUR in revenue for fiscal year 2025, down 77.9% from 12.62 million EUR in fiscal year 2024.
$180.95 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Whitehawk Therapeutics, Inc. (WHWK), Corbus Pharmaceuticals Holdings, Inc. (CRBP), Adagene Inc. (ADAG), Compass Therapeutics, Inc. (CMPX).